- The share
- Arjo B
- 05 jun 2020 16:24
- 4,83 EUR (-1,37%)
Arjo interim report January-March 2020
”We deliver a strong start to the year with an organic growth of 3,4%. We see clear results from our efficiency measures and our operating profit increases by over 20%, while at the same time having a solid financial position. The effects from the coronapandemic becomes clear at the end of the quarter with an increased demand for hospital beds and therapeutic mattresses, but also lower focus on products and services not directly addressing Covid-19,” says Joacim Lindoff, President & CEO. “We put an intense quarter behind us and I find it very satisfying that we can support healthcare during this challenging time. At the same time, we are facing increased uncertainty, making it difficult to assess the effects for the remaining part of the year,” adds Joacim Lindoff.
January-March 2020 in brief
• Net sales increased by 6,5% to SEK 2,273 M (2,134).
Net sales grew organically by 3,4%.
• Adjusted EBITDA increased 7,8% to SEK 445 M (413).
• Operating profit before restructuring activities increased by 20,8% to SEK 203 M (168).
• Profit after financial items increased to SEK 140 M (133).
• Earnings per share increased to SEK 0.39 (0.37).
• Cash flow from operations increased to SEK 287 M (180).
• Cash conversion increased to 70.1% (43,6).
• The Group pauses its forecast for the full-year due to the uncertainty regarding the coronavirus.
• The Annual General Meeting and Capital Markets Day 2020 are postponed due to Covid-19
Fund managers, analysts and the media are invited to a teleconference on April 27 at 08.00 CET. Please see details below to join the conference:
Sweden: +46 (0)8 5033 6574
UK: +44 (0)330 336 9125
USA: +1 323-794-2093
A presentation will be held during the telephone conference. To access the presentation, please use this link: https://slideassist.webcasts.com/starthere.jsp?ei=1300315
Alternatively, use the following link to download the presentation:
A recording of the teleconference will be available for 90 days via the following link: https://slideassist.webcasts.com/starthere.jsp?ei=1300315
For more information, please contact:
Executive Vice President, Marketing Communications & Public Relations
Tel: +46 (0)10 335 4810
Investor Relations & Corporate Communications
Tel: +46 (0)10 335 4866
This information is information that Arjo AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 07:00 CET on April 27, 2020.
At Arjo, we are committed to improving the everyday lives of people affected by reduced mobility and age-related health challenges. With products and solutions that ensure ergonomic patient handling, personal hygiene, disinfection, diagnostics, and the effective prevention of pressure ulcers and venous thromboembolism, we help professionals across care environments to continually raise the standard of safe and dignified care. Arjo has approximately 6,000 employees worldwide and customers in over 100 countries. In 2019, Arjo sales amounted to approximately SEK 8.9 billion. Arjo is listed on Nasdaq Stockholm and its head office is located in Malmö, Sweden. Everything we do, we do with people in mind. www.arjo.comDownload as PDF